文献速递神经康复

每日振动触觉刺激缓解卒中后痉挛不劣于甚至优于肉毒毒素

Daily Vibrotactile Stimulation Exhibits Equal or Greater Spasticity Relief Than Botulinum Toxin in Stroke.
PubMed 文献 · Arch Phys Med Rehabil · 2023-05-04

这项前瞻性两臂干预研究纳入20例慢性卒中患者,评估VTS手套每日使用3小时、持续8周对痉挛性肌张力增高的效果。结果显示改良Ashworth和改良Tardieu评分在第8周平均降低0.9和0.7,停止使用4周后降低1.1和0.9;在11例常规使用BTX-A的患者中,6例VTS期间改良Ashworth改善幅度大于BTX-A,8例症状最低水平出现在VTS期间。

要点

  • 慢性卒中患者每日使用VTS手套3小时、持续8周可显著降低痉挛评分
  • 停止VTS手套使用4周后痉挛改善仍持续甚至进一步扩大
  • 超过半数常规使用BTX-A的患者在VTS期间获得等同或更优的症状缓解

核心结论

  • 每日VTS手套刺激可缓解卒中后痉挛和肌张力增高,对超过半数常规使用BTX-A的患者提供等同或更优的症状缓解。

研究设计与样本

  • 前瞻性两臂干预研究,纳入20例慢性卒中患者(平均年龄54岁,平均卒中病程6.9年)。
  • 一组为既往接受BTX-A标准治疗者,在末次注射12周后开始干预;另一组为不使用BTX-A者。
  • 参与者被指导每日在家或日常活动中使用VTS手套3小时,持续8周。
  • 主要结局为改良Ashworth量表和改良Tardieu量表从基线至第8周(VTS手套使用结束)及第12周(停止使用4周后)的差值。
  • 使用BTX-A者在开始VTS手套前12周内也接受评估,以监测BTX-A对痉挛性肌张力增高的效果。

主要发现

  • 每日VTS手套使用期间及之后均发现痉挛性肌张力增高的临床有意义差异。
  • 第8周时改良Ashworth和改良Tardieu评分平均分别降低0.9(P=.0014)和0.7(P=.0003)。
  • 停止VTS手套使用1个月后改良Ashworth和改良Tardieu评分平均分别降低1.1(P=.00025)和0.9(P=.0001)。
  • 在11例使用BTX-A的参与者中,6例在VTS手套使用期间改良Ashworth评分变化更大(平均-1.8 vs BTX-A平均-1.6)。
  • 在11例使用BTX-A的参与者中,8例在VTS手套使用期间症状水平最低(优于BTX-A期间)。

关键数值与推荐

  • 改良Ashworth评分在第8周平均降低0.9(P=.0014),停止使用4周后平均降低1.1(P=.00025)。
  • 改良Tardieu评分在第8周平均降低0.7(P=.0003),停止使用4周后平均降低0.9(P=.0001)。
  • BTX-A组中6/11例VTS期间改良Ashworth变化大于BTX-A期间(平均-1.8 vs 平均-1.6)。
  • BTX-A组中8/11例在VTS期间症状水平最低(优于BTX-A期间)。

临床怎么用

  • VTS手套可作为慢性卒中患者痉挛管理的可行家庭干预手段,每日使用3小时、持续8周。
  • 对常规接受BTX-A治疗的患者,VTS手套可能提供等同或更优的痉挛缓解,可考虑作为辅助或替代选择。
  • 停止VTS手套使用后痉挛改善仍可维持至少4周,提示疗效具有持续效应。

局限性

  • 研究样本量较小(N=20),结果需更大样本验证。
  • 研究为前瞻性两臂干预研究,非随机对照设计,可能存在选择偏倚。
  • BTX-A组与不使用BTX-A组之间未进行直接随机比较,组间可比性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the feasibility and efficacy of the VibroTactile Stimulation (VTS) Glove, a wearable device that provides VTS to the impaired limb to reduce spastic hypertonia. DESIGN: Prospective 2-arm intervention study-including 1 group of patients who use Botulinum toxin (BTX-A) for spasticity and 1 group of patients who do not use BTX-A. SETTING: Participants were recruited through rehabilitation and neurology clinics. PARTICIPANTS: Patients with chronic stroke (N=20; mean age=54 years, mean time since stroke=6.9 years). Patients who were previously receiving the standard of care (BTX-A injection) were eligible to participate and started the intervention 12 weeks after their last injection. INTERVENTION: Participants were instructed to use the VTS Glove for 3 hours daily, at home or during everyday activities, for 8 weeks. MAIN OUTCOME MEASURES: Spasticity was assessed with the Modified Ashworth Scale and the Modified Tardieu Scale at baseline and then at 2-week intervals for 12 weeks. Primary outcomes were the difference from baseline and at week 8 (end of VTS Glove use) and week 12 (4 weeks after stopping VTS Glove use). Patients who were receiving BTX-A were also assessed during the 12 weeks preceding the start of VTS Glove use to monitor the effect of BTX-A on spastic hypertonia. Range of motion and participant feedback were also studied. RESULTS: A clinically meaningful difference in spastic hypertonia was found during and after daily VTS Glove use. Modified Ashworth and Modified Tardieu scores were reduced by an average of 0.9 (P=.0014) and 0.7 (P=.0003), respectively, at week 8 of daily VTS Glove use, and by 1.1 (P=.00025) and 0.9 (P=.0001), respectively, 1 month after stopping VTS Glove use. For participants who used BTX-A, 6 out of 11 showed greater change in Modified Ashworth ratings during VTS Glove use (mean=-1.8 vs mean=-1.6 with BTX-A) and 8 out of 11 showed their lowest level of symptoms during VTS Glove use (vs BTX-A). CONCLUSIONS: Daily stimulation from the VTS Glove provides relief of spasticity and hypertonia. For more than half of the participants who had regularly used BTX-A, the VTS Glove provided equal or greater symptom relief.

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Seim C, Chen B, Han C, et al. Daily Vibrotactile Stimulation Exhibits Equal or Greater Spasticity Relief Than Botulinum Toxin in Stroke. Arch Phys Med Rehabil. 2023. PMID: 37149017. doi:10.1016/j.apmr.2023.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。